The American Cancer Society has estimated that 76 100 new invasive melanomas will be diagnosed and 9710 people will die of melanoma in 2014 in the United States.
1 Despite newly available targeted and immunomodulatory agents,
2-5 systemic therapies rarely lead to cures. Thus, early detection of primary melanomas followed by surgical excision remains critical for good outcomes. While recognition of all melanomas can be difficult, lack of brown or black color in amelanotic melanoma at the time of clinical diagnosis removes a defining characteristic for melanoma identification. Several studies indicate that amelanotic melanoma is associated with adverse survival because the tumors are more advanced at diagnosis; however, the majority of studies included only small numbers of amelanotic melanoma cases entered at single study sites and used a clinical, not pathologic, definition of amelanotic melanoma or lacked centralized pathologic review.